Virology and Immunology of Hepatitis Viruses
Summary
- Therapy for HBV infection currently includes peginterferon and nucleos(t)ide analogues that inhibit HBV polymerase[Terrault 2018; EASL HBV]
- Peginterferon alfa-2a is administered for 48 weeks and leads to a 32% chance of HBeAg seroconversion and a 3% chance of HBsAg loss[EASL HBV]
- A subset of patients will require retreatment
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content